Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pere Fontova

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Molecular Therapy. Nucleic Acids|May 17, 2021
The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritisJordi Guiteras, Élia Ripoll, Núria Bolaños, et al.
Frontiers in Pharmacology|April 5, 2021
Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney TransplantationPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Pharmaceutics|September 27, 2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudyZeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, et al.
Frontiers in Immunology|March 29, 2021
Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney TransplantationMaria Meneghini, Elena Crespo, Matthias Niemann, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 18, 2024
Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapiesCristina Benítez-García, David Martínez-García, Martin Kotev, et al.
Kidney International|June 30, 2023
A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian PredictionNuria Lloberas, Josep M Grinyó, Helena Colom, et al.
Pharmaceutics|May 27, 2023
The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus FormulationsPere Fontova, Lisanne N van Merendonk, Anna Vidal-Alabró, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Clinical Pharmacology and Therapeutics|February 24, 2021
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant RecipientsPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Frontiers in Immunology|July 14, 2022
Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney TransplantationElena Crespo, Anna Vidal-Alabró, Thomas Jouve, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Molecular Therapy. Nucleic Acids|May 17, 2021
The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritisJordi Guiteras, Élia Ripoll, Núria Bolaños, et al.
Frontiers in Pharmacology|April 5, 2021
Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney TransplantationPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Pharmaceutics|September 27, 2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudyZeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, et al.
Frontiers in Immunology|March 29, 2021
Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney TransplantationMaria Meneghini, Elena Crespo, Matthias Niemann, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 18, 2024
Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapiesCristina Benítez-García, David Martínez-García, Martin Kotev, et al.
Kidney International|June 30, 2023
A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian PredictionNuria Lloberas, Josep M Grinyó, Helena Colom, et al.
Pharmaceutics|May 27, 2023
The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus FormulationsPere Fontova, Lisanne N van Merendonk, Anna Vidal-Alabró, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Clinical Pharmacology and Therapeutics|February 24, 2021
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant RecipientsPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Frontiers in Immunology|July 14, 2022
Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney TransplantationElena Crespo, Anna Vidal-Alabró, Thomas Jouve, et al.
Pageof 3